Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | F7 | P08709 | 3/20 | 0.50 |
| ▸ | F3 | P13726 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17307884 | 0.98 | ALDH1A1 (0.57) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL17307880 | 0.95 | ADORA3 (0.59) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL31108848 | 0.91 | CYP4F2 (0.69) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL20713329 | 0.91 | CYP4F2 (0.69) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL31108907 | 0.91 | CYP4F2 (0.69) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL20713255 | 0.91 | CYP4F2 (0.69) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL20613555 | 0.91 | CYP4F2 (0.69) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL2879705 | 0.88 | ADORA3 (0.53) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL16386596 | 0.87 | ACLY (0.51) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL20597774 | 0.85 | CYP4F2 (0.81) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327455-A1 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease | JIVA PHARMA, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327455-A1 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease | JIVA PHARMA, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20150344402-A1 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease | JIVA PHARMA, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344402-A1 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease | JIVA PHARMA, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344402-A1 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease | PPARA, PPARG, PPARD | ALDH1A1 2441/4885CYP3A4 840/4885ALOX15 64/4885 |
| US-20170327455-A1 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease | PPARA, PPARG, PPARD | ALDH1A1 2441/4885CYP3A4 840/4885ALOX15 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.